Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Novo specifically requested semaglutide be added to the FDA’s Demonstrable Difficulties for Compounding lists, citing complexities around formulations, delivery mechanisms, dosage forms ...

In December, the FDA removed tirzepatide from the list of drugs subject to shortages, a regulatory status which makes it legal for compounding pharmacies to produce their own versions of a drug on a ...

Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.

The compounded semaglutide gummy is available through ... company focused on connecting patients with doctors and licensed compounding pharmacies to deliver personalized metabolic health programs.

Semaglutide, one of several appetite suppressing drugs called GLP-1s, helped dampen her "food noise." Several of Dunham's family members are also on GLP-1s, and their Thanksgiving food bill is ...

"FDA continues to monitor supply and demand for these products." Since the shortage began, specialty and compounding pharmacies have been allowed to sell off-brand versions of the weight loss drug.